Biosimilar Bummer: FDA Postpones Celltrion Infliximab Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Pending information requests lead to delay of the March 17 meeting.
You may also be interested in...
Aprogen’s Biosimilar Remicade To Hit Japan Next Year?
South Korea-based biotech firm Aprogen's biosimilar version of Remicade (Johnson & Johnson's infliximab) is set to complete a Phase III clinical study in Japan as early as this month. The company’s Japanese partner will then file for local regulatory approval immediately after completing the trial and aims to launch the product in the country in the latter half of next year.
Saving Face? Cell Therapeutics Withdraws Pixantrone NDA Ahead Of Advisory Committee Review
Company’s announcement that it pulled the NDA for its investigational non-Hodgkin’s lymphoma treatment comes after the sponsor would have received FDA’s background briefing document for the Feb. 9 Oncologic Drugs Advisory Committee meeting.
US FDA Hopes Food, Inspection Office Reorg Bolsters Innovative Clinical Trial Adoption
Ensuring inspectors understand the innovative trial designs in use before an inspection will be important to increasing industry confidence in their use, CDER Director Patrizia Cavazzoni said.